메뉴 건너뛰기




Volumn 31, Issue 11, 2008, Pages 509-513

Safety of spironolactone use in ambulatory heart failure patients

Author keywords

Heart failure; Hyperkalemia; Renal function deterioration; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; BIOLOGICAL MARKER; CREATININE; DIURETIC AGENT; SPIRONOLACTONE;

EID: 60849111431     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20284     Document Type: Article
Times cited : (29)

References (14)
  • 1
    • 0033517302 scopus 로고    scopus 로고
    • The effect of spironolactone on morbidity and mortality in patients with severe heart failure
    • MD, MD, MD, MD, MD
    • Pitt B MD, Zannad F MD, Remme WJ MD, Cody R MD, Castaigne A MD, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341(10):709-717
    • (1999) N Engl J Med , vol.341 , Issue.10 , pp. 709-717
    • Pitt, B.1    Zannad, F.2    Remme, W.J.3    Cody, R.4    Castaigne, A.5
  • 3
    • 10644242516 scopus 로고    scopus 로고
    • Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure
    • DOI 10.1016/j.ahj.2004.10.005, PII S0002870304007501
    • Tamirisa KP MD, Aaronson KD MD, MS, Koelling TM MD. Spironolactone- induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004;148(6):971-978 (Pubitemid 39646969)
    • (2004) American Heart Journal , vol.148 , Issue.6 , pp. 971-978
    • Tamirisa, K.P.1    Aaronson, K.D.2    Koelling, T.M.3
  • 4
    • 3442886513 scopus 로고    scopus 로고
    • Rates of Hyperkalemia after publication of the randomized Aldactone evaluation study
    • MD, PhD, Pharm. D, MPH, MD, BA, PhD
    • Juurlink DN MD, PhD, Mamdani MM Pharm. D, MPH, Lee DS MD, Kopp A BA, Austin PC PhD, et al.: Rates of Hyperkalemia after publication of the randomized Aldactone evaluation study. N Engl J Med 2004;351(6):543-551
    • (2004) N Engl J Med , vol.351 , Issue.6 , pp. 543-551
    • Juurlink, D.N.1    Mamdani, M.M.2    Lee, D.S.3    Kopp, A.4    Austin, P.C.5
  • 5
    • 0035870772 scopus 로고    scopus 로고
    • Life-threatening hyperkalemia during combined therapy with angiotensin converting enzyme inhibitors and spironolactone: An analysis of 25 cases
    • MD, MD, PhD, MD, MD, PhD
    • Schepkens H MD, Vanholder R MD, PhD, Billiouw JM MD, Lameire N MD, PhD: Life-threatening hyperkalemia during combined therapy with angiotensin converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 2001; 110: 438-441
    • (2001) Am J Med , vol.110 , pp. 438-441
    • Schepkens, H.1    Vanholder, R.2    Billiouw, J.M.3    Lameire, N.4
  • 6
    • 0035315810 scopus 로고    scopus 로고
    • Serious adverse events experienced by patients with chronic heart failure taking spironolactone
    • MD, MD
    • Berry C MD, McMurray JJ MD. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001;85:E8
    • (2001) Heart , vol.85
    • Berry, C.1    McMurray, J.J.2
  • 7
    • 33751114892 scopus 로고    scopus 로고
    • Reports of hyperkalemia after publication of RALES - A pharmacovigilance study
    • MD, MPH, MD, Pharm.D, PhD
    • Hauben M MD, MPH, Reich L MD, Gerrits CM Pharm.D, PhD. Reports of hyperkalemia after publication of RALES-a pharmacovigilance study. Pharmacoepidemiol Drug Saf 2006; 15(11): 775-783
    • (2006) Pharmacoepidemiol Drug Saf , vol.15 , Issue.11 , pp. 775-783
    • Hauben, M.1    Reich, L.2    Gerrits, C.M.3
  • 8
    • 0242637043 scopus 로고    scopus 로고
    • Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: Retrospective study
    • Svensson M MD, Gustafsson F MD, Galatius S MD, Hildebrandt PR, MD, Atar D MD. Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 2003;327:1141-1142 (Pubitemid 37421809)
    • (2003) British Medical Journal , vol.327 , Issue.7424 , pp. 1141-1142
    • Svensson, M.1    Gustafsson, F.2    Galatius, S.3    Hildebrandt, P.R.4    Atar, D.5
  • 9
    • 33646484997 scopus 로고    scopus 로고
    • Appropriateness of spironolactone prescribing in heart failure patients: A population-based study
    • MD, MD, PhD, Pharm.D, MPH, MD, MSc
    • Ko DT MD, Juurlink DN MD, PhD, Mamdani MM Pharm.D, MPH, You JJ MD, Wang JT MSc, et al.: Appropriateness of spironolactone prescribing in heart failure patients: A population-based study. J Card Fail 2006;12(3):205-210
    • (2006) J Card Fail , vol.12 , Issue.3 , pp. 205-210
    • Ko, D.T.1    Juurlink, D.N.2    Mamdani, M.M.3    You, J.J.4    Wang, J.T.5
  • 11
    • 0142117284 scopus 로고    scopus 로고
    • Aldosterone blockade in patients with systolic left ventricular dysfunction
    • MD
    • Pitt B MD: Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 2003;108:1790-1794
    • (2003) Circulation , vol.108 , pp. 1790-1794
    • Pitt, B.1
  • 12
    • 0034651798 scopus 로고    scopus 로고
    • Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
    • MBChB, MRCP, MD, FRCP
    • Farquharson CA MBChB, MRCP, Struthers AD MD, FRCP: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:1722-1728
    • (2000) Circulation , vol.101 , pp. 1722-1728
    • Farquharson, C.A.1    Struthers, A.D.2
  • 13
    • 0035370038 scopus 로고    scopus 로고
    • Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure
    • MRCP, SD MD, FRCP, MD, FRCP, FESC
    • Yee KM MRCP, Pringle SD MD, FRCP, Struthers AD MD, FRCP, FESC: Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2002;37(7):1800-1807
    • (2002) J Am Coll Cardiol , vol.37 , Issue.7 , pp. 1800-1807
    • Yee, K.M.1    Pringle2    Struthers, A.D.3
  • 14
    • 0035168937 scopus 로고    scopus 로고
    • Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction
    • MD, FACC, FESC, MD, MD, MD
    • Modena MG MD, FACC, FESC, Aveta P MD, Menozzi A MD, Rossi R MD: Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141(1):41-46
    • (2001) Am Heart J , vol.141 , Issue.1 , pp. 41-46
    • Modena, M.G.1    Aveta, P.2    Menozzi, A.3    Rossi, R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.